NMDA Receptor Agonists: Relationships between Structure and Biological Activity

  • Bjarke Ebert
  • Ulf Madsen
  • Tommy Nørskov Johansen
  • Povl Krogsgaard-Larsen
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 287)


The acidic amino acids L-aspartic acid (ASP) and, in particular, L-glutamic acid (GLU) are generally accepted to be the major excitatory amino acid (EAA) neurotransmitters in the mammalian central nervous system (CNS). Hyperactivity of central EAA neuronal pathways has been associated with the etiology of certain neurodegenerative diseases, such as status epilepticus, Huntington’s chorea and dementia of the Alzheimer type (Lodge, 1988; Rothman and Olney, 1986; Greenamyre 1986; Greenamyre et al., 1988; Bridges et al., 1988). In Alzheimer patients a regional degeneration of cholinergic, noradrenergic and serotonergic neurones is observed (Narang and Cutler, 1986).


Status Epilepticus Excitatory Amino Acid Kainic Acid Ibotenic Acid Excitatory Amino Acid Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bridges, R. J., Geddes, J. W., Monaghan, D. T., and Cotman, C. W., 1988, Excitatory amino acid receptors in Alzheimer’s disease, in “Excitatory Amino Acids in Health and Disease,” D. Lodge, ed., J. Wiley&Sons, Chichester, pp. 321–335.Google Scholar
  2. Coyle, J. T., 1983, Neurotoxic action of kainic acid, J. Neurochem., 41: 1–11.PubMedCrossRefGoogle Scholar
  3. Deutsch, S. I., Mastropaolo, J., Schwartz, B. L., Rosse, R. B., and Morihisa, J. M., 1989, A “glutamatergic hypothesis” of schizophrenia: rationale for pharmacotherapy with glycine, Clin. Neuropharmacol., 12:1–13.PubMedCrossRefGoogle Scholar
  4. Greenamyre, J. T., 1986, The role of glutamate in neurotransmission and in neurologic disease, Arch. Neurol., 43:1058–1063.PubMedCrossRefGoogle Scholar
  5. Greenamyre, J. T., Maragos, W. F., Albin, R. L., Penney, J. B., and Young, A. B., 1988, Glutamate transmission and toxicity in Alzheimer’s disease, Prog. Neuro-Psychopharmacol. Biol. Psychiat., 12:421–430.CrossRefGoogle Scholar
  6. Hansen, J. J. and Krogsgaard-Larsen, P., 1990, Structural, conformational, and stereochemical requirements of central excitatory amino acid receptors, Med. Res. Rev., 10:55–94.PubMedCrossRefGoogle Scholar
  7. Johnson, R. L. and Koerner, J. F., 1988, Excitatory amino acid neurotransmission, J. Med. Chem., 31:2057–2066.PubMedCrossRefGoogle Scholar
  8. Krogsgaard-Larsen, P., Brehm, L., Johansen, J. S., Vinzents, P., Lauridsen, J., and Curtis, D. R., 1985, Synthesis and structure-activity studies on excitatory amino acids structurally related to ibotenic acid, J. Med. Chem., 28:673–679.PubMedCrossRefGoogle Scholar
  9. Krogsgaard-Larsen, P., Honoré, T., Hansen, J. J., Curtis, D. R., and Lodge, D., 1980, New class of glutamate agonists structurally related to ibotenic acid, Nature (London), 284:64–66.CrossRefGoogle Scholar
  10. Krogsgaard-Larsen, P., Nielsen, E. O., and Curtis, D. R., 1984, Ibotenic acid analogues. Synthesis and biological in vitro activity of confor-mationally restricted agonists at central excitatory amino acid receptors, J. Med. Chem., 27:585–591.PubMedCrossRefGoogle Scholar
  11. Lodge, D., ed., 1988, “Excitatory Amino Acids in Health and Disease”, J. Wiley&Sons, Chichester.Google Scholar
  12. Madsen, U., Brehm, L., Schaumburg, K., Jorgensen, F. S., and Krogsgaard-Larsen, P., 1990, Relationship between structure, conformational flexibility and biological activity of agonists and antagonists at the N-methyl-D-aspartic acid subtype of excitatory amino acid receptors, J. Med. Chem., 33:374–380.PubMedCrossRefGoogle Scholar
  13. McLennan, H., 1983, Receptors for the excitatory amino acids in the mammalian central nervous system, Prog. Neurobiol., 20:251–271.PubMedCrossRefGoogle Scholar
  14. Narang, P. K. and Cutler, N. R., 1986, Pharmacotherapy in Alzheimer’s disease: basis and rationale, Prog. Neuropsychopharmacol. Biol. Psychiat., 10:519–531.CrossRefGoogle Scholar
  15. Nielsen, E. O., Schousboe, A., Hansen, S. H., and Krogsgaard-Larsen, P., 1985, Excitatory amino acids: studies on the biochemical and chemical stability of ibotenic acid and related compounds, J. Neurochem., 45:725–731.PubMedCrossRefGoogle Scholar
  16. Rothman, S. M. and Olney, J. W., 1986, Glutamate and the pathology of hypoxic/ischemic brain damage, Ann. Neurol., 19:105–111.PubMedCrossRefGoogle Scholar
  17. Shinozaki, H., 1988, Pharmacology of the glutamate receptor, Prog. Neurobiol., 30:399–435.PubMedCrossRefGoogle Scholar
  18. Watkins, J. C., Krogsgaard-Larsen, P., and Honoré, T., 1990, Structure-activity relations in the development of excitatory amino acid receptor agonists and competitive antagonists, Trends Pharmacol. Sci., 11:25–33.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Bjarke Ebert
    • 1
  • Ulf Madsen
    • 1
  • Tommy Nørskov Johansen
    • 1
  • Povl Krogsgaard-Larsen
    • 1
  1. 1.Department of Organic ChemistryThe Royal Danish School of PharmacyCopenhagenDenmark

Personalised recommendations